All the Therapeutic System Drugs
Cannabinoids, Specific Immunoglobulin. Palvizumab 50 mg, 100mg. VIAL(PWDR) + DILUENT: 1 X 50 mg+ 4 ml
diluent, 100 mg + 10 ml diluent.
15 mg/kg by I.M. inject. 1 x mthly
during course of RSV season. See lit.
Preven. of serious lower resp. tract dis.
requir. hospitalis. caused by RSV in child.
at high risk for RSV dis.:
Child. born at 35 wks. of gestation or less
and less than 6 mths. of age at the onset
of the RSV season. Child. less than 2 yrs. of age and requir.
tmt. for bronchopulm. dysplasia within
the last 6 mths.
Children less than 2 yrs. of age and with
haemodyn. signif.congen. heart dis.
C/I: Hypersens. to palvizumab or any
compon. of formula, or other humanized
Nucleotide Reverse Transcriptase Inhibitor. Aciclovir 200 mg, 400 mg. TABS: 2, 10, 20, 25, 30, 60, 70, 100.
Herpes simplex: 200 mg (1 tab) every 4
hrs (5 x dly). Herpes zoster (shingles):
Single dose of 800 mg (2 x 400 mg
tabs) every 4 hrs (5 x dly). Start tmt. as
soon as possible aft. onset of rash
(within 72 hrs. from onset of itch.;
chickenpox: within 24 hrs.) Child:
Herpes simplex: 2 yrs and over: Adult
dose. Under 2 yrs: 1/2 adult dose. See
Tmt. and proph. of infects. caused by
herpes simplex and varicella zoster virus.
To be considered for tmt. of chicken pox
in certain groups at increased risk of
severe varicella or its complicat. See lit.
Nucleotide Reverse Transcriptase Inhibitor. Aciclovir 250 mg. VIALS (pwdr. for sol. for IV inject): 5 x 10
ml. See lit.
Tmt. herpes simplex infects., severe initial
genital herpes in non-immune comp.
pts., prophylax. herpes simplex infects. in
immune-comp. pts. Tmt. varicella zoster
infects., herpes simplex encephalit.,
herpes simplex infects. in neonate/infant
up to 3 mths old.
NS5A Protein Inhibitor. Daclatasvir Dihydrochloride 30 mg. F.C. TABS.: 14. 60 mg×1/d, to be taken orally with/ without meal. Daclatasvir must be admin. in comb. with other med.products. See lit.
Indicated in comb. with other meds.products for the tmt. of chronic HCV infec.in adults.
C/I: Hypersens. Coadmin. with meds. that strongly induce cytochr. CYP3A4 and P-gp (e.g. phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, systemic dexamethasone, and the herbal product St John’s wort.
Nucleoside Reverse Transcriptase Inhibitor. Entecavir 0.5 mg, 1 mg. TABS.:30: Compens. liver dis.: Nucleoside naive pts.: 0.5 mg×1/d, with/without food. Lamivudine-refractory pts.: 1 mg ×1/d, without food. Decompens. liver dis.: 1 mg ×1/d, without food. For pts. with lamivudine-refractory hepatitis B, see lit.
Tmt. of chronic HBV infec. in adults with: Compens. liver dis. and evidence of active viral replic. persist. elevated serum ALT levels and histolog. evidence of active inflam. and/ or fibrosis. Decompens. liver dis. For both compens. and decompens. liver dis. , this indic. is based on clinical trial data in nucleoside naive pts. with HBeAg positive and HBeAg negative HBV infec. With respect to pts. with lamivudine-refract. hepatitis B.
C/I: Hypersens., lact.
Antivirals. Sofosbuvir 400 mg, Velpatasvir 100 mg. F.C. TABS.: 28. One tab., taken oral.,
once dly. with or without food. See lit.
Treatment of chronic hepatitis C virus
(HCV) infection in adults.
C/I: Hypersens. Use with strong P gp and strong CYP induc.: Med. products that are strong P glycoprotein (P-gp) and/or strong cytoch. P450 (CYP) induc. (carbamazepine, phenobarbital, phenytoin, rifampicin, rifabutin, and St. John’s wort). Co
admin. will signific. decrease sofosbuvir
or velpatasvir plasma conc. and could
result in loss of efficacy of this formul.